Wei Xiaolei, Shen Xueli, Yuan Qiuchen, Shen Chen, Liang Tao, Gao Rui, Li Shuping, Cui Lingling
School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department of Rehabilitation Center for Elderly, Beijing Rehabilitation Hospital Affiliated to Capital Medical University, Beijing, China.
BMJ Open. 2024 Dec 9;14(12):e086457. doi: 10.1136/bmjopen-2024-086457.
Frailty significantly influences the prognosis of elderly patients diagnosed with heart failure. The assessment of frailty is a critical initial step in the management of these patients, as a systematic and precise evaluation facilitates the identification of individuals at high risk. This identification enables timely and targeted interventions, which can subsequently reduce the likelihood of adverse cardiovascular events and improve the quality of life for elderly patients with heart failure. Nevertheless, there exists a notable deficiency in research regarding the most effective frailty assessment tools specifically for elderly patients with heart failure in China. The objective of this study is to identify the frailty assessment tool that demonstrates the highest predictive value for outcomes in this population.
This study is a multicentre, prospective cohort investigation that commenced in October 2023 across three tertiary hospitals in Beijing, China. Employing a continuous enrolment strategy, the study encompasses all elderly patients diagnosed with heart failure who are undergoing either outpatient or inpatient treatment, continuing until an adequate sample size is achieved. Follow-up evaluations are scheduled every 3 months from the point of patient enrolment, extending until the 12th month post-enrolment. Comprehensive data collection, which includes demographic information, heart failure-related metrics, frailty assessments and significant biochemical test results, is conducted through face-to-face interviews at baseline.
Participant inclusion will depend on obtaining written informed consent from the patient or guardian. The trial protocol was approved by the Central Ethics Committee of Beijing Hospital. The approval letter number is 2023BJYYEC-356-01. Outcomes of the study will be published in a peer-reviewed scientific journal.
衰弱对诊断为心力衰竭的老年患者的预后有显著影响。衰弱评估是这些患者管理中的关键初始步骤，因为系统而精确的评估有助于识别高危个体。这种识别能够实现及时且有针对性的干预，进而降低不良心血管事件的发生可能性，并改善老年心力衰竭患者的生活质量。然而，在中国，针对老年心力衰竭患者最有效的衰弱评估工具的研究存在显著不足。本研究的目的是确定对该人群预后具有最高预测价值的衰弱评估工具。
本研究是一项多中心前瞻性队列研究，于2023年10月在中国北京的三家三级医院开展。采用连续入组策略，该研究涵盖所有诊断为心力衰竭且正在接受门诊或住院治疗的老年患者，持续进行直至获得足够样本量。从患者入组时起，每3个月安排一次随访评估，持续至入组后第12个月。通过基线时的面对面访谈进行全面的数据收集，包括人口统计学信息、心力衰竭相关指标、衰弱评估和重要生化检测结果。
参与者的纳入将取决于获得患者或监护人的书面知情同意。试验方案已获北京医院中央伦理委员会批准。批准文号为2023BJYYEC - 356 - 01。研究结果将发表在同行评审的科学期刊上。
